Cargando…

Posterior Reversible Encephalopathy Syndrome due to High Dose Corticosteroids for an MS Relapse

Increased blood pressure is a known adverse effect associated with corticosteroids but little is published regarding the risk with the high doses used in multiple sclerosis (MS). A 53-year-old female with known relapsing remitting MS presented with a new brainstem relapse. Standard of care treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrow, Sarah A., Rana, Robina, Lee, Donald, Paul, Terri, Mahon, Jeffrey L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460203/
https://www.ncbi.nlm.nih.gov/pubmed/26101676
http://dx.doi.org/10.1155/2015/325657
_version_ 1782375343337766912
author Morrow, Sarah A.
Rana, Robina
Lee, Donald
Paul, Terri
Mahon, Jeffrey L.
author_facet Morrow, Sarah A.
Rana, Robina
Lee, Donald
Paul, Terri
Mahon, Jeffrey L.
author_sort Morrow, Sarah A.
collection PubMed
description Increased blood pressure is a known adverse effect associated with corticosteroids but little is published regarding the risk with the high doses used in multiple sclerosis (MS). A 53-year-old female with known relapsing remitting MS presented with a new brainstem relapse. Standard of care treatment for an acute MS relapse, 1250 mg of oral prednisone for 5 days, was initiated. She developed an occipital headache and dizziness and felt generally unwell. These symptoms persisted after treatment was complete. On presentation to medical attention, her blood pressure was 199/110 mmHg, although she had no history of hypertension. MRI changes were consistent with posterior reversible encephalopathy syndrome (PRES), demonstrating abnormal T2 signal in both thalami, the posterior occipital and posterior parietal white matter with mild sulcal effacement. As her pressure normalized with medication, her symptoms resolved and the MRI changes improved. No secondary cause of hypertension was found. This is the first reported case of PRES secondary to high dose corticosteroid use for an MS relapse without a history of hypertension and with no other secondary cause of hypertension identified. This rare complication should be considered in MS patients presenting with a headache or other neurological symptoms during treatment for a relapse.
format Online
Article
Text
id pubmed-4460203
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-44602032015-06-22 Posterior Reversible Encephalopathy Syndrome due to High Dose Corticosteroids for an MS Relapse Morrow, Sarah A. Rana, Robina Lee, Donald Paul, Terri Mahon, Jeffrey L. Case Rep Neurol Med Case Report Increased blood pressure is a known adverse effect associated with corticosteroids but little is published regarding the risk with the high doses used in multiple sclerosis (MS). A 53-year-old female with known relapsing remitting MS presented with a new brainstem relapse. Standard of care treatment for an acute MS relapse, 1250 mg of oral prednisone for 5 days, was initiated. She developed an occipital headache and dizziness and felt generally unwell. These symptoms persisted after treatment was complete. On presentation to medical attention, her blood pressure was 199/110 mmHg, although she had no history of hypertension. MRI changes were consistent with posterior reversible encephalopathy syndrome (PRES), demonstrating abnormal T2 signal in both thalami, the posterior occipital and posterior parietal white matter with mild sulcal effacement. As her pressure normalized with medication, her symptoms resolved and the MRI changes improved. No secondary cause of hypertension was found. This is the first reported case of PRES secondary to high dose corticosteroid use for an MS relapse without a history of hypertension and with no other secondary cause of hypertension identified. This rare complication should be considered in MS patients presenting with a headache or other neurological symptoms during treatment for a relapse. Hindawi Publishing Corporation 2015 2015-05-26 /pmc/articles/PMC4460203/ /pubmed/26101676 http://dx.doi.org/10.1155/2015/325657 Text en Copyright © 2015 Sarah A. Morrow et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Morrow, Sarah A.
Rana, Robina
Lee, Donald
Paul, Terri
Mahon, Jeffrey L.
Posterior Reversible Encephalopathy Syndrome due to High Dose Corticosteroids for an MS Relapse
title Posterior Reversible Encephalopathy Syndrome due to High Dose Corticosteroids for an MS Relapse
title_full Posterior Reversible Encephalopathy Syndrome due to High Dose Corticosteroids for an MS Relapse
title_fullStr Posterior Reversible Encephalopathy Syndrome due to High Dose Corticosteroids for an MS Relapse
title_full_unstemmed Posterior Reversible Encephalopathy Syndrome due to High Dose Corticosteroids for an MS Relapse
title_short Posterior Reversible Encephalopathy Syndrome due to High Dose Corticosteroids for an MS Relapse
title_sort posterior reversible encephalopathy syndrome due to high dose corticosteroids for an ms relapse
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460203/
https://www.ncbi.nlm.nih.gov/pubmed/26101676
http://dx.doi.org/10.1155/2015/325657
work_keys_str_mv AT morrowsaraha posteriorreversibleencephalopathysyndromeduetohighdosecorticosteroidsforanmsrelapse
AT ranarobina posteriorreversibleencephalopathysyndromeduetohighdosecorticosteroidsforanmsrelapse
AT leedonald posteriorreversibleencephalopathysyndromeduetohighdosecorticosteroidsforanmsrelapse
AT paulterri posteriorreversibleencephalopathysyndromeduetohighdosecorticosteroidsforanmsrelapse
AT mahonjeffreyl posteriorreversibleencephalopathysyndromeduetohighdosecorticosteroidsforanmsrelapse